A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies
- 30 June 1989
- journal article
- clinical trial
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 16, 53-57
- https://doi.org/10.1016/0305-7372(89)90023-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.Journal of Clinical Oncology, 1988
- In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.Journal of Clinical Oncology, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Human Interleukin 2: Molecular Biology, Physiology and Clinical PossibilitiesImmunobiology, 1986
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.The Journal of Experimental Medicine, 1982